Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT-Reference-Cited by-同舟云学术

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT

Published:2013-05-20 Issue:10 Volume:48 Page:1324-1328
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Innes A J,Beattie R,Sergeant R,Damaj G,Foroni L,Marin D,Kanfer E,Mielke S,Milojkovic D,MacDonald D,Pavlu J,Rahemtulla A,Roberts I,Slade D,Bray E,Goldman J,Apperley J,Szydlo R,Dazzi F,Rezvani K

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201369.pdf

Reference27 articles.

1. Pavlu J, Szydlo RM, Goldman JM, Apperley J . Three decades of transplantation for chronic myeloid leukaemia: what have we learned? Blood 2011; 117: 755–763.

2. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485–501.

3. Craddock CF . Full-intensity and reduced intensity allogeneic stem cell transplantation in AML. Bone marrow Transplant 2008; 31: 415–423.

4. Ballen KK, Korelth J, Yi-Bin Chen, Dey BR, Spitzer TR . Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplantation. Blood 2012; 119: 1972–1980.

5. Oudshoorn M, van Walraven SM, Bakker JN, Lie JL, V D Zanden HG, Heemskerk MB et al. Hematopoietic stem cell donor selection: the Europdonor experience. Hum Immunol 2006; 67: 405–412.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions;OncoTargets and Therapy;2023-01

2. Allogeneic Hematopoietic Cell Transplantation in CML: When and How?;Pathogenesis and Treatment of Leukemia;2023

3. Prophylactic donor lymphocyte infusion for relapse prevention: a meta-analysis;Japanese Journal of Clinical Oncology;2020-02-24

4. Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation;Bone Marrow Transplantation;2018-12-13

5. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect;Experimental Hematology;2017-04